公开(公告)号：EP4051696A1

公开(公告)日：2022-09-07

申请号：EP20803651.7

申请日：2020-10-28

申请人： Pfizer Inc.

发明人： ANDERSON, Annaliesa Sybil ,  CHEN, Wei ,  CHORRO, Laurent Oliver ,  CHU, Ling ,  DONALD, Robert G.K. ,  GRIFFOR, Matthew Curtis ,  GU, Jianxin ,  GUAN, Zeqiang ,  KIM, Jin-Hwan ,  KODALI, Srinivas ,  LOMBERK, Scott Ellis ,  LOTVIN, Jason Arnold ,  MERCHANT, Nishith ,  MORAN, Justin Keith ,  PAN, Rosalind ,  PRASAD, Avvari Krishna ,  RUPPEN, Mark Edward ,  SINGH, Suddham ,  STEAD, David Robert ,  TAKANE, Karen Kiyoko ,  CHE, Ye

IPC分类号： C07K14/245

公开(公告)号：EP3393512A1

公开(公告)日：2018-10-31

申请号：EP16816405.1

申请日：2016-12-09

申请人： Pfizer Inc.

发明人： CHE, Ye ,  DORMITZER, Philip Ralph ,  GRIBENKO, Alexey Vyacheslavovich ,  HANDKE, Luke David ,  PRASAD, Avvari Krishna ,  QIU, Xiayang ,  RUPPEN, Mark Edward ,  SONG, Xi ,  SWANSON, Kena Anne ,  KODALI, Srinivas ,  XU, Xin ,  EFFEREN, KariAnn Sweeney ,  CAI, Ping ,  TOMPKINS, Kristin Rachael ,  NUNEZ, Lorna Del Pilar

IPC分类号： A61K39/155 ,  A61K39/12 ,  C07K14/005

CPC分类号： A61K39/155 ,  A61K39/12 ,  A61K2039/575 ,  C07K14/005 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/40 ,  C07K2319/70 ,  C07K2319/735 ,  C12N7/00 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571

摘要： The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：EP2964665B1

公开(公告)日：2018-08-01

申请号：EP14714380.4

申请日：2014-03-05

申请人： Pfizer Inc.

发明人： ANDERSON, Annaliesa Sybil ,  DILTS, Deborah Ann ,  JANSEN, Kathrin Ute ,  MORAN, Justin Keith ,  RUPPEN, Mark Edward ,  VIDUNAS, Eugene Joseph

IPC分类号： C07K14/22 ,  C12N15/62 ,  A61K39/095

CPC分类号： C07K14/22 ,  A61K39/092 ,  A61K39/095 ,  A61K2039/6037 ,  A61K2039/6068 ,  C07K14/3156 ,  C07K2319/00 ,  C07K2319/55

摘要： In one aspect, the invention relates to an isolated polypeptide including the amino acid sequence of a carrier polypeptide and the amino acid sequence of an ORF2086 polypeptide. In another aspect, the invention relates to an immunogenic conjugate including ORF2086 polypeptide and a carrier polypeptide. The invention further includes immunogenic compositions and methods for inducing an immune response against Neisseria meningitidis in a mammal.

公开(公告)号：EP3840777A2

公开(公告)日：2021-06-30

申请号：EP19784128.1

申请日：2019-08-20

申请人： Pfizer Inc.

发明人： DONALD, Robert G. K. ,  ANDERSON, Annaliesa Sybil ,  CHORRO, Laurent Oliver ,  GU, Jianxin ,  KIM, Jin-Hwan ,  KODALI, Srinivas ,  LOTVIN, Jason Arnold ,  MORAN, Justin Keith ,  PAN, Rosalind ,  PRASAD, Avvari Krishna ,  RUPPEN, Mark Edward ,  SINGH, Suddham ,  CHU, Ling ,  LOMBERK, Scott Ellis ,  TAKANE, Karen Kiyoko ,  MERCHANT, Nishith ,  CHEN, Wei

IPC分类号： A61K39/108 ,  A61K39/385 ,  A61P31/04 ,  C07K16/12

公开(公告)号：EP3687570A1

公开(公告)日：2020-08-05

申请号：EP18779805.3

申请日：2018-09-14

申请人： Pfizer Inc.

发明人： ANDERSON, Annaliesa Sybil ,  DONALD, Robert G.K. ,  FLINT, Michael James ,  JANSEN, Kathrin Ute ,  KITCHIN, Nicholas Randolph Everard ,  MORAN, Justin Keith ,  PEDNEAULT, Louise ,  PRIDE, Michael W. ,  RUPPEN, Mark Edward ,  WEBBER, Christopher Frederick

IPC分类号： A61K39/08 ,  C07K16/12 ,  C07K14/33 ,  A61K39/00

公开(公告)号：EP2964665A2

公开(公告)日：2016-01-13

申请号：EP14714380.4

申请日：2014-03-05

申请人： Pfizer Inc.

发明人： ANDERSON, Annaliesa Sybil ,  DILTS, Deborah Ann ,  JANSEN, Kathrin Ute ,  MORAN, Justin Keith ,  RUPPEN, Mark Edward ,  VIDUNAS, Eugene Joseph

IPC分类号： C07K14/22 ,  C12N15/62 ,  A61K39/095

CPC分类号： C07K14/22 ,  A61K39/092 ,  A61K39/095 ,  A61K2039/6037 ,  A61K2039/6068 ,  C07K14/3156 ,  C07K2319/00 ,  C07K2319/55

摘要： In one aspect, the invention relates to an isolated polypeptide including the amino acid sequence of a carrier polypeptide and the amino acid sequence of an ORF2086 polypeptide. In another aspect, the invention relates to an immunogenic conjugate including ORF2086 polypeptide and a carrier polypeptide. The invention further includes immunogenic compositions and methods for inducing an immune response against Neisseria meningitidis in a mammal.

摘要翻译： 一方面，本发明涉及包含载体多肽的氨基酸序列和ORF2086多肽的氨基酸序列的分离的多肽。 另一方面，本发明涉及包含ORF2086多肽和载体多肽的免疫原性缀合物。 本发明还包括用于在哺乳动物中诱导针对脑膜炎奈瑟氏球菌的免疫应答的免疫原性组合物和方法。

公开(公告)号：EP2909307A2

公开(公告)日：2015-08-26

申请号：EP13786535.8

申请日：2013-10-07

申请人： Pfizer Inc.

发明人： JANSEN, Kathrin Ute ,  ANDERSON, Annaliesa Sybil ,  DONALD, Robert G.K. ,  FLINT, Michael James ,  KALYAN, Narender Kumar ,  LOTVIN, Jason Arnold ,  SIDHU, Maninder K ,  MORAN, Justin Keith ,  RUPPEN, Mark Edward ,  SUN, Weiqiang

IPC分类号： C12N1/20 ,  C07K14/33

CPC分类号： C12N9/1051 ,  C07K14/33 ,  C12N1/20

摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant
Clostridium difficile toxin A and/or a mutant
Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type
C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing
C. difficile toxins.

摘要翻译： 一方面，本发明涉及包含突变型艰难梭菌毒素A和/或突变型艰难梭菌毒素B的免疫原性组合物。突变毒素可以包括具有至少一个突变的葡糖基转移酶结构域和至少具有至少一个突变的半胱氨酸蛋白酶结构域 一个突变，相对于相应的野生型艰难梭菌毒素。 突变毒素可以包括至少一个化学交联的氨基酸。 另一方面，本发明涉及用于培养艰难梭菌和产生艰难梭菌毒素的方法和组合物。

公开(公告)号：EP3912990A1

公开(公告)日：2021-11-24

申请号：EP21171606.3

申请日：2013-10-07

申请人： Pfizer Inc.

发明人： JANSEN, Kathrin Ute ,  ANDERSON, Annaliesa Sybil ,  DONALD, Robert G.K. ,  FLINT, Michael James ,  KALYAN, Narender Kumar ,  LOTVIN, Jason Arnold ,  SIDHU, Maninder K ,  MORAN, Justin Keith ,  RUPPEN, Mark Edward ,  SUN, Weiqiang

IPC分类号： C07K14/33 ,  A61K39/08

摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

公开(公告)号：EP3292146A1

公开(公告)日：2018-03-14

申请号：EP16722381.7

申请日：2016-04-29

申请人： Pfizer Inc.

发明人： ANDERSON, Annaliesa Sybil ,  BHUPENDER BHALLA, Amardeep Singh ,  DONALD, Robert G.K. ,  GU, Jianxin ,  JANSEN, Kathrin Ute ,  KAINTHAN, Rajesh Kumar ,  KHANDKE, Lakshmi ,  KIM, Jin-Hwan ,  LIBERATOR, Paul ,  PRASAD, Avvari Krishna ,  RUPPEN, Mark Edward ,  SCULLY, Ingrid Lea ,  SINGH, Suddham ,  YANG, Cindy Xudong

IPC分类号： C07K16/12 ,  A61K39/09

CPC分类号： A61K39/092 ,  A61K39/39 ,  A61K39/40 ,  A61K47/10 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/55577 ,  A61K2039/6037 ,  A61K2039/70 ,  C07K16/1275 ,  C07K16/44 ,  Y02A50/484

摘要： The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.